Gynecologic Oncology Group quality assurance audits: Analysis and initiatives for improvement

John A. Blessing, Sally A. Bialy, Charles W. Whitney, Bette L. Stonebraker, Frederick Stehman

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background The Gynecologic Oncology Group (GOG) is a multi-institution, multi-discipline Cooperative Group funded by the National Cancer Institute (NCI) to conduct clinical trials which investigate the treatment, prevention, control, quality of survivorship, and translational science of gynecologic malignancies. In 1982, the NCI initiated a program of on-site quality assurance audits of participating institutions. Each is required to be audited at least once every 3 years. In GOG, the audit mandate is the responsibility of the GOG Quality Assurance Audit Committee and it is centralized in the Statistical and Data Center (SDC). Each component (Regulatory, Investigational Drug Pharmacy, Patient Case Review) is classified as Acceptable, Acceptable, follow-up required, or Unacceptable. Purpose To determine frequently occurring deviations and develop focused innovative solutions to address them. Methods A database was created to examine the deviations noted at the most recent audit conducted at 57 GOG parent institutions during 2004-2007. Cumulatively, this involved 687 patients and 306 protocols. Results The results documented commendable performance: Regulatory (39 Acceptable, 17 Acceptable, follow-up, 1 Unacceptable); Pharmacy (41 Acceptable, 3 Acceptable, follow-up, 1 Unacceptable, 12 N/A): Patient Case Review (31 Acceptable, 22 Acceptable, follow-up, 4 Unacceptable). The nature of major and lesser deviations was analyzed to create and enhance initiatives for improvement of the quality of clinical research. As a result, Group-wide proactive initiatives were undertaken, audit training sessions have emphasized recurring issues, and GOG Data Management Subcommittee agendas have provided targeted instruction and training. Limitations The analysis was based upon parent institutions only; affiliate institutions and Community Clinical Oncology Program participants were not included, although it is assumed their areas of difficulty are similar. Conclusions The coordination of the GOG Quality Assurance Audit program in the SDC has improved data quality by enhancing our ability to identify frequently occurring deviations and develop innovative solutions to avoid or minimize their occurrence in the future.

Original languageEnglish
Pages (from-to)390-399
Number of pages10
JournalClinical Trials
Volume7
Issue number4
DOIs
StatePublished - Aug 2010

Fingerprint

National Cancer Institute (U.S.)
Investigational Drugs
Medical Oncology
Quality Improvement
Quality Control
Survival Rate
Clinical Trials
Databases
Research
Neoplasms
Therapeutics
Data Accuracy

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology

Cite this

Gynecologic Oncology Group quality assurance audits : Analysis and initiatives for improvement. / Blessing, John A.; Bialy, Sally A.; Whitney, Charles W.; Stonebraker, Bette L.; Stehman, Frederick.

In: Clinical Trials, Vol. 7, No. 4, 08.2010, p. 390-399.

Research output: Contribution to journalArticle

Blessing, John A. ; Bialy, Sally A. ; Whitney, Charles W. ; Stonebraker, Bette L. ; Stehman, Frederick. / Gynecologic Oncology Group quality assurance audits : Analysis and initiatives for improvement. In: Clinical Trials. 2010 ; Vol. 7, No. 4. pp. 390-399.
@article{b736bf3ed9434dd996b3bc8a4ee95301,
title = "Gynecologic Oncology Group quality assurance audits: Analysis and initiatives for improvement",
abstract = "Background The Gynecologic Oncology Group (GOG) is a multi-institution, multi-discipline Cooperative Group funded by the National Cancer Institute (NCI) to conduct clinical trials which investigate the treatment, prevention, control, quality of survivorship, and translational science of gynecologic malignancies. In 1982, the NCI initiated a program of on-site quality assurance audits of participating institutions. Each is required to be audited at least once every 3 years. In GOG, the audit mandate is the responsibility of the GOG Quality Assurance Audit Committee and it is centralized in the Statistical and Data Center (SDC). Each component (Regulatory, Investigational Drug Pharmacy, Patient Case Review) is classified as Acceptable, Acceptable, follow-up required, or Unacceptable. Purpose To determine frequently occurring deviations and develop focused innovative solutions to address them. Methods A database was created to examine the deviations noted at the most recent audit conducted at 57 GOG parent institutions during 2004-2007. Cumulatively, this involved 687 patients and 306 protocols. Results The results documented commendable performance: Regulatory (39 Acceptable, 17 Acceptable, follow-up, 1 Unacceptable); Pharmacy (41 Acceptable, 3 Acceptable, follow-up, 1 Unacceptable, 12 N/A): Patient Case Review (31 Acceptable, 22 Acceptable, follow-up, 4 Unacceptable). The nature of major and lesser deviations was analyzed to create and enhance initiatives for improvement of the quality of clinical research. As a result, Group-wide proactive initiatives were undertaken, audit training sessions have emphasized recurring issues, and GOG Data Management Subcommittee agendas have provided targeted instruction and training. Limitations The analysis was based upon parent institutions only; affiliate institutions and Community Clinical Oncology Program participants were not included, although it is assumed their areas of difficulty are similar. Conclusions The coordination of the GOG Quality Assurance Audit program in the SDC has improved data quality by enhancing our ability to identify frequently occurring deviations and develop innovative solutions to avoid or minimize their occurrence in the future.",
author = "Blessing, {John A.} and Bialy, {Sally A.} and Whitney, {Charles W.} and Stonebraker, {Bette L.} and Frederick Stehman",
year = "2010",
month = "8",
doi = "10.1177/1740774510372535",
language = "English",
volume = "7",
pages = "390--399",
journal = "Clinical Trials",
issn = "1740-7745",
publisher = "SAGE Publications Ltd",
number = "4",

}

TY - JOUR

T1 - Gynecologic Oncology Group quality assurance audits

T2 - Analysis and initiatives for improvement

AU - Blessing, John A.

AU - Bialy, Sally A.

AU - Whitney, Charles W.

AU - Stonebraker, Bette L.

AU - Stehman, Frederick

PY - 2010/8

Y1 - 2010/8

N2 - Background The Gynecologic Oncology Group (GOG) is a multi-institution, multi-discipline Cooperative Group funded by the National Cancer Institute (NCI) to conduct clinical trials which investigate the treatment, prevention, control, quality of survivorship, and translational science of gynecologic malignancies. In 1982, the NCI initiated a program of on-site quality assurance audits of participating institutions. Each is required to be audited at least once every 3 years. In GOG, the audit mandate is the responsibility of the GOG Quality Assurance Audit Committee and it is centralized in the Statistical and Data Center (SDC). Each component (Regulatory, Investigational Drug Pharmacy, Patient Case Review) is classified as Acceptable, Acceptable, follow-up required, or Unacceptable. Purpose To determine frequently occurring deviations and develop focused innovative solutions to address them. Methods A database was created to examine the deviations noted at the most recent audit conducted at 57 GOG parent institutions during 2004-2007. Cumulatively, this involved 687 patients and 306 protocols. Results The results documented commendable performance: Regulatory (39 Acceptable, 17 Acceptable, follow-up, 1 Unacceptable); Pharmacy (41 Acceptable, 3 Acceptable, follow-up, 1 Unacceptable, 12 N/A): Patient Case Review (31 Acceptable, 22 Acceptable, follow-up, 4 Unacceptable). The nature of major and lesser deviations was analyzed to create and enhance initiatives for improvement of the quality of clinical research. As a result, Group-wide proactive initiatives were undertaken, audit training sessions have emphasized recurring issues, and GOG Data Management Subcommittee agendas have provided targeted instruction and training. Limitations The analysis was based upon parent institutions only; affiliate institutions and Community Clinical Oncology Program participants were not included, although it is assumed their areas of difficulty are similar. Conclusions The coordination of the GOG Quality Assurance Audit program in the SDC has improved data quality by enhancing our ability to identify frequently occurring deviations and develop innovative solutions to avoid or minimize their occurrence in the future.

AB - Background The Gynecologic Oncology Group (GOG) is a multi-institution, multi-discipline Cooperative Group funded by the National Cancer Institute (NCI) to conduct clinical trials which investigate the treatment, prevention, control, quality of survivorship, and translational science of gynecologic malignancies. In 1982, the NCI initiated a program of on-site quality assurance audits of participating institutions. Each is required to be audited at least once every 3 years. In GOG, the audit mandate is the responsibility of the GOG Quality Assurance Audit Committee and it is centralized in the Statistical and Data Center (SDC). Each component (Regulatory, Investigational Drug Pharmacy, Patient Case Review) is classified as Acceptable, Acceptable, follow-up required, or Unacceptable. Purpose To determine frequently occurring deviations and develop focused innovative solutions to address them. Methods A database was created to examine the deviations noted at the most recent audit conducted at 57 GOG parent institutions during 2004-2007. Cumulatively, this involved 687 patients and 306 protocols. Results The results documented commendable performance: Regulatory (39 Acceptable, 17 Acceptable, follow-up, 1 Unacceptable); Pharmacy (41 Acceptable, 3 Acceptable, follow-up, 1 Unacceptable, 12 N/A): Patient Case Review (31 Acceptable, 22 Acceptable, follow-up, 4 Unacceptable). The nature of major and lesser deviations was analyzed to create and enhance initiatives for improvement of the quality of clinical research. As a result, Group-wide proactive initiatives were undertaken, audit training sessions have emphasized recurring issues, and GOG Data Management Subcommittee agendas have provided targeted instruction and training. Limitations The analysis was based upon parent institutions only; affiliate institutions and Community Clinical Oncology Program participants were not included, although it is assumed their areas of difficulty are similar. Conclusions The coordination of the GOG Quality Assurance Audit program in the SDC has improved data quality by enhancing our ability to identify frequently occurring deviations and develop innovative solutions to avoid or minimize their occurrence in the future.

UR - http://www.scopus.com/inward/record.url?scp=77955579034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955579034&partnerID=8YFLogxK

U2 - 10.1177/1740774510372535

DO - 10.1177/1740774510372535

M3 - Article

C2 - 20576671

AN - SCOPUS:77955579034

VL - 7

SP - 390

EP - 399

JO - Clinical Trials

JF - Clinical Trials

SN - 1740-7745

IS - 4

ER -